{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:40:21Z","timestamp":1767994821341,"version":"3.49.0"},"reference-count":185,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pneumologie"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Das vorliegende Positionspapier (AWMF) zur Therapie der Sarkoidose der Deutschen Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin (DGP) wurde 2023 als deutschsprachige Erg\u00e4nzung und Aktualisierung der internationalen Leitlinien der European Respiratory Society (ERS) aus dem Jahre 2021 verfasst. Sie enth\u00e4lt 5 im Konsensusverfahren abgestimmte Empfehlungen in Form von PICO-Fragen (Patients, Intervention, Comparison, Outcomes), die im Hintergrundtext der 4 Kapitel erl\u00e4utert werden: Diagnosesicherung und Monitoring der Erkrankung unter Therapie, allgemeine Therapieempfehlungen, Therapie der Hautsarkoidose, Therapie der kardialen Sarkoidose.<\/jats:p>","DOI":"10.1055\/a-2259-1046","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T23:57:11Z","timestamp":1708991831000},"page":"151-166","source":"Crossref","is-referenced-by-count":8,"title":["Therapie der Sarkoidose. Ein Positionspapier der Deutschen Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin (DGP)"],"prefix":"10.1055","volume":"78","author":[{"given":"Dirk","family":"Skowasch","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II \u2013 Sektion Pneumologie, Universit\u00e4tsklinikum Bonn, Bonn, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr interstitielle und seltene Lungenerkrankungen, Klinik f\u00fcr Pneumologie, Ruhrlandklinik, Universit\u00e4tsmedizin Essen, Essen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Buschulte","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr seltene und interstitielle Lungenerkrankungen, Thoraxklinik, Universit\u00e4tsklinikum Heidelberg und Deutsches Zentrum f\u00fcr Lungenforschung (DZL) \u2013 Heidelberg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Kneidinger","sequence":"additional","affiliation":[{"name":"Lungentransplantation und interstitielle Lungenerkrankungen, Medizinische Klinik und Poliklinik V, M\u00fcnchen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Korsten","sequence":"additional","affiliation":[{"name":"Klinische Rheumatologie und rheumatologische Intensivmedizin, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Lungenzentrum Mainz, Klinik f\u00fcr Pneumologie, Beatmungs- und Schlafmedizin, Marienhaus Klinikum Mainz und Klinik f\u00fcr Pneumologie, Zentrum f\u00fcr Thoraxerkrankungen, Universit\u00e4tsmedizin Mainz, Mainz, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"M\u00fcller-Quernheim","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Pneumologie, Department Innere Medizin, Uniklinik Freiburg, Medizinische Fakult\u00e4t, Freiburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"Innere Medizin, Lungen- und Bronchialheilkunde, Krankenhaus Barmherzige Br\u00fcder, Regensburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Prasse","sequence":"additional","affiliation":[{"name":"Lungenfibrose und interstitielle Lungenerkrankungen, Medizinische Hochschule Hannover, Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Quadder","sequence":"additional","affiliation":[{"name":"Deutsche Sarkoidose-Vereinigung, gemeinn\u00fctziger e.\u200aV. (DSV)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Sander","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Rheumatologie, Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas C.","family":"Schupp","sequence":"additional","affiliation":[{"name":"Respiratory and Infectious Medicine, Hannover Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Sitter","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Chirurgische Forschung, Fachbereich Medizin, Philipps-Universit\u00e4t Marburg, Marburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Stachetzki","sequence":"additional","affiliation":[{"name":"Sarkoidose-Netzwerk e.\u200aV."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Groh\u00e9","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Pneumologie, Evangelische Lungenklinik, Berlin, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"ref1","first-page":"736","article-title":"Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"E D Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"R P Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","author":"M Thillai","year":"2021","journal-title":"Thorax"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s41030-021-00161-w","article-title":"A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist","volume":"7","author":"A S Melani","year":"2021","journal-title":"Pulm Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"E D Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"D Valeyre","year":"2014","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/17512433.2018.1486706","article-title":"Treatment of sarcoidosis: grading the evidence","volume":"11","author":"W E James","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref9","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"R P Baughman","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"R P Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumabin patients with chronic sarcoidosis","volume":"44","author":"M A Judson","year":"2014","journal-title":"Eur Respir J"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"R P Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","author":"M Thillai","year":"2021","journal-title":"Thorax"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaoncol.2016.6435","article-title":"Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia","volume":"3","author":"N Ertz-Archambault","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation","volume":"115","author":"A Galor","year":"2008","journal-title":"Ophthalmology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"S Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"A DM Vorselaars","year":"2013","journal-title":"Chest"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"E E Lower","year":"1995","journal-title":"Arch Intern Med"},{"key":"ref19","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study","volume":"36","author":"C Fang","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1183\/09031936.99.14511179","article-title":"Treatment of chronic sarcoidosis with an azathioprine\/prednisolone regimen","volume":"14","author":"J M\u00fcller-Quernheim","year":"1999","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/resp.14001","article-title":"Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective \u2018target trial\u2019 emulated with Swedish real-world data","volume":"26","author":"M Rossides","year":"2021","journal-title":"Respirology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"A Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/kew214","article-title":"Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study","volume":"55","author":"E Lange","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis","volume":"359","author":"C Pagnoux","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","article-title":"Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn\u02bcs disease: a randomised, investigator-blind study","volume":"35","author":"S Ardizzone","year":"2003","journal-title":"Dig Liver Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2133.2012.10872.x","article-title":"A randomized trial of methotrexate vs. azathioprine for severe atopic eczema: a critical appraisal","volume":"166","author":"A N Patel","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET positive sarcoidosis","volume":"46","author":"A D Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"A D Vorselaars","year":"2014","journal-title":"Eur Respir J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","article-title":"Efficacy and safety of infliximab biosimilar Inflectra((R)) in severe sarcoidosis","volume":"138S","author":"M C Schimmelpennink","year":"2018","journal-title":"Respir Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","article-title":"Infliximab Therapy in Refractory Sarcoidosis: A Multicenter Real-World Analysis","volume":"23","author":"A Sakkat","year":"2022","journal-title":"Resp Research"},{"key":"ref32","first-page":"201","article-title":"A double-blind, randomized, placebocontrolled trial of infliximab in patients with active pulmonary sarcoidosis","volume":"23","author":"M D Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref33","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis","volume":"31","author":"M Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref34","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"R P Baughman","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1378\/chest.08-1347","article-title":"The treatment of lupus pernio: results of 116 treatment courses in 54 patients","volume":"135","author":"E Stagaki","year":"2009","journal-title":"Chest"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series","volume":"89","author":"J M Gelfand","year":"2017","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","article-title":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients","volume":"47","author":"Y Jamilloux","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent","volume":"345","author":"J Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/annrheumdis-2011-200490","article-title":"Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis","volume":"71","author":"M Schoels","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"M A Judson","year":"2014","journal-title":"Eur Respir J"},{"key":"ref41","first-page":"46","article-title":"Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis","volume":"31","author":"N J Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s11845-015-1363-9","article-title":"Adalimumab for refractory pulmonary sarcoidosis","volume":"185","author":"P A Minnis","year":"2016","journal-title":"Ir J Med Sci"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0873-2159(15)30403-7","article-title":"Tumor necrosis factor inhibition in treating sarcoidosis: the American experience","volume":"13","author":"R P Baughman","year":"2007","journal-title":"Revista Portuguesa de Pneumonologia"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"H A Crommelin","year":"2016","journal-title":"Respir Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"R P Baughman","year":"2005","journal-title":"Chest"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"J P Utz","year":"2003","journal-title":"Chest"},{"key":"ref47","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"R P Baughman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"D H Sahoo","year":"2011","journal-title":"Eur Respir J"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.clpt.2004.01.016","article-title":"Peripheral neuropathy in patients treated with leflunomide","volume":"75","author":"R A Bonnel","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"ref50","first-page":"1906","article-title":"Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD","volume":"31","author":"G W Cannon","year":"2004","journal-title":"J Rheumatol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/ajrccm.160.1.9809024","article-title":"Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis","volume":"160","author":"M Baltzan","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"302S","DOI":"10.1111\/j.0954-6820.1964.tb05780.x","article-title":"Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis","volume":"425","author":"L E Siltzbach","year":"1964","journal-title":"Acta Med Scand"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis","volume":"159","author":"W P Drake","year":"2021","journal-title":"Chest"},{"key":"ref54","first-page":"121","article-title":"Steroid sparing effects of pentoxifylline in pulmonary sarcoidosis","volume":"26","author":"M K Park","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1164\/ajrccm.156.5.9506031","article-title":"Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial","volume":"156","author":"C P Wyser","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"K R Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"A U Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.healun.2013.08.007","article-title":"The registry of the International Society for Heart and Lung Transplantation","volume":"32","author":"R D Yusen","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"00738","DOI":"10.1183\/23120541.00738-2022","article-title":"Sarcoidosis lung transplantation waitlist mortality, a national registry database study","volume":"9","author":"D C Fleitas Sosa","year":"2023","journal-title":"ERJ Open Res"},{"key":"ref60","first-page":"92","article-title":"Lung transplantation for pulmonary sarcoidosis","volume":"36","author":"K C Meyer","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1056\/NEJM199704243361706","article-title":"Sarcoidosis","volume":"336","author":"L S Newman","year":"1997","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/pgmj.74.877.649","article-title":"Cutaneous sarcoidosis","volume":"74","author":"N J Wilson","year":"1998","journal-title":"Postgrad Med J"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccm.2015.08.010","article-title":"Cutaneous sarcoidosis","volume":"36","author":"K A Wanat","year":"2015","journal-title":"Clin Chest Med"},{"key":"ref64","first-page":"86","article-title":"Sarcoidosis on tattoos: a review of the literature from 1939 to 2011","volume":"30","author":"N Kluger","year":"2013","journal-title":"Sarcoidosis VDLD"},{"key":"ref65","first-page":"83","article-title":"Sarcoidal granuloma presenting on tattoo: a report of a Japanese female patient and a review of Japanese published work","volume":"33","author":"M Ohtsuka","year":"2016","journal-title":"Sarcoidosis VDLD"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00128071-200809030-00003","article-title":"Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems","volume":"9","author":"R P Baughman","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2133.1985.tb04859.x","article-title":"Lupus pernio: a clinico-radiological study of thirty-five cases","volume":"112","author":"M A Spiteri","year":"1985","journal-title":"Br J Dermatol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1378\/chest.08-1347","article-title":"The treatment of lupus pernio: results of 116 treatment courses in 54 patients","volume":"135","author":"E Stagaki","year":"2009","journal-title":"Chest"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clindermatol.2007.03.011","article-title":"Evidence-based therapy for cutaneous sarcoidosis","volume":"25","author":"R P Baughman","year":"2007","journal-title":"Clin Dermatol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1378\/chest.08-1347","article-title":"The treatment of lupus pernio: results of 116 treatment courses in 54 patients","volume":"135","author":"E Stagaki","year":"2009","journal-title":"Chest"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"R P Baughman","year":"2012","journal-title":"Arch Dermatol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00128071-200809030-00003","article-title":"Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems","volume":"9","author":"R P Baughman","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1164\/rccm.201410-1785OC","article-title":"Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure","volume":"191","author":"M A Judson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King\u02bcs Sarcoidosis Questionnaire for the assessment of health status","volume":"68","author":"A S Patel","year":"2013","journal-title":"Thorax"},{"key":"ref76","first-page":"136","article-title":"High frequency ultrasound: a novel instrument to quantify granuloma burden in cutaneous sarcoidosis","volume":"34","author":"M H Noe","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2230.2005.01729.x","article-title":"Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore","volume":"30","author":"W S Chong","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2340\/00015555726971","article-title":"Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing","volume":"72","author":"G Volden","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archderm.1995.01690170121026","article-title":"Lupus pernio: successful treatment with a potent topical corticosteroid","volume":"131","author":"K A Khatri","year":"1995","journal-title":"Arch Dermatol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0190-9622(81)70017-3","article-title":"Intralesional corticosteroids","volume":"4","author":"J P Callen","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaad.2006.06.019","article-title":"Cutaneous sarcoidosis therapy updated","volume":"56","author":"C Badgwell","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"R P Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"ref83","first-page":"153","article-title":"Cutaneous sarcoidosis: a case series from a regional hospital in Hong Kong","volume":"20","author":"M M Chang","year":"2012","journal-title":"Hong Kong J Dermatol Venereol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/jdv.13760","article-title":"Epidemiology of cutaneous sarcoidosis, 1976\u20132013: a population-based study from Olmsted County, Minnesota","volume":"30","author":"P Ungprasert","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref85","first-page":"372","article-title":"Comparison of cutaneous sarcoidosis with systemic sarcoidosis: a retrospective analysis","volume":"7","author":"C Tong","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2230.2009.03400.x","article-title":"A retrospective analysis of 34 patients with cutaneous sarcoidosis assessed in a dermatology department","volume":"35","author":"B Collin","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaad.2005.10.001","article-title":"Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease?","volume":"54","author":"I Ahmed","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref88","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"R P Baughman","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"M A Judson","year":"2008","journal-title":"Eur Respir J"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"M A Judson","year":"2014","journal-title":"Eur Respir J"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"R J Pariser","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"ref92","first-page":"1224","article-title":"A randomized, investigator masked double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis","volume":"336","author":"C Droitcourt","year":"1997","journal-title":"N Engl J Med"},{"key":"ref93","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"R P Baughman","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1378\/chest.122.1.227","article-title":"Thalidomide for chronic sarcoidosis","volume":"122","author":"R P Baughman","year":"2002","journal-title":"Chest"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0041-3879(67)80033-3","article-title":"Chloroquine in the treatment of sarcoidosis","volume":"48","author":"British Tuberculosis Association","year":"1967","journal-title":"Tubercle"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"302S","DOI":"10.1111\/j.0954-6820.1964.tb05780.x","article-title":"Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis","volume":"425","author":"L E Siltzbach","year":"1964","journal-title":"Acta Med Scand"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0190-9622(90)70246-E","article-title":"Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas","volume":"23","author":"E Jones","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"E E Lower","year":"1995","journal-title":"Arch Intern Med"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0190-9622(91)70071-9","article-title":"Weekly low-dose methotrexate therapy for cutaneous sarcoidosis","volume":"24","author":"G F Webster","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-3476(97)70306-8","article-title":"Low-dose methotrexate therapy for childhood sarcoidosis","volume":"130","author":"A Gedalia","year":"1997","journal-title":"J Pediatr"},{"key":"ref101","first-page":"S335","article-title":"Methotrexate in the treatment of cutaneous sarcoidosis","volume":"11","author":"R Rajendran","year":"1994","journal-title":"Sarcoidosis"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","author":"R P Baughman","year":"2012","journal-title":"Arch Dermatol"},{"key":"ref103","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"R P Baughman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate versus azathioprine in second line therapy of sarcoidosis","volume":"144","author":"A D Vorselaars","year":"2013","journal-title":"Chest"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","article-title":"Efficacy of mycophenolate mofetil in sarcoidosis","volume":"108","author":"N Hamzeh","year":"2014","journal-title":"Respir Med"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"D H Sahoo","year":"2011","journal-title":"Eur Respir J"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamadermatol.2013.4646","article-title":"Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study","volume":"149","author":"W P Drake","year":"2013","journal-title":"JAMA Dermatol"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis","volume":"159","author":"W P Drake","year":"2021","journal-title":"Chest"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis","volume":"379","author":"W Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdcr.2021.08.012","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis","volume":"16","author":"R Talty","year":"2021","journal-title":"JAAD Case Rep"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series","volume":"84","author":"K L Kerkemeyer","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"R P Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/pgmj.74.877.649","article-title":"Cutaneous sarcoidosis","volume":"74","author":"N J Wilson","year":"1998","journal-title":"Postgrad Med J"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"R P Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/CIRCULATIONAHA.109.851352","article-title":"Detection of myocardial damage in patients with sarcoidosis","volume":"120","author":"M R Patel","year":"2009","journal-title":"Circulation"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/01.CIR.58.6.1204","article-title":"Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis","volume":"58","author":"K J Silverman","year":"1978","journal-title":"Circulation"},{"key":"ref117","first-page":"325","article-title":"Cardiovascular magnetic resonance-guided diagnosis of cardiac affection in a Caucasian sarcoidosis population","volume":"32","author":"C Pizarro","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1513\/AnnalsATS.201902-119CME","article-title":"Update in cardiac sarcoidosis","volume":"16","author":"M L Ribeiro Neto","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/heartjnl-2013-305187","article-title":"Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis","volume":"100","author":"T Ise","year":"2014","journal-title":"Heart"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"e005001","DOI":"10.1161\/CIRCIMAGING.116.005001","article-title":"Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis","volume":"9","author":"E Hulten","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","article-title":"Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis","volume":"63","author":"R Blankstein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Y Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ejhf.1319","article-title":"Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres","volume":"20","author":"L A Fussner","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chest.2016.08.1457","article-title":"Cardiac sarcoidosis: the impact of age and implanted devices on survival","volume":"151","author":"Y Zhou","year":"2017","journal-title":"Chest"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s12350-018-01504-y","article-title":"The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis","volume":"27","author":"R J Flores","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.amjcard.2015.06.021","article-title":"Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis","volume":"116","author":"R Kandolin","year":"2015","journal-title":"Am J Cardiol"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jcmg.2017.04.020","article-title":"Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis","volume":"11","author":"B W Sperry","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ejhf.205","article-title":"Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis","volume":"17","author":"E Joyce","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"15","author":"S M Al-Khatib","year":"2018","journal-title":"Heart Rhythm"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"e007488","DOI":"10.1161\/CIRCEP.119.007488","article-title":"Assessment of the 2017 AHA\/ACC\/HRS guideline recommendations for implantable cardioverter-defibrillator implantation in cardiac sarcoidosis","volume":"12","author":"F Kazmirczak","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"D H Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"ref132","first-page":"124","article-title":"Cardiac sarcoidosis: diagnostic and therapeutic algorithms","volume":"68","author":"U Costabel","year":"2014","journal-title":"Pneumologie"},{"key":"ref133","first-page":"24","article-title":"Diagnostics and treatment of cardiac sarcoidosis \u2013 consensus paper of the German Respiratory Society (DGP) and the German Cardiac Society (DGK)","volume":"74","author":"D Skowasch","year":"2020","journal-title":"Pneumologie"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2021.11.061","article-title":"The role of electrophysiology study in risk stratification of cardiac sarcoidosis patients: Meta-analysis and systemic review","volume":"349","author":"M Adhaduk","year":"2022","journal-title":"Int J Cardiol"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"106712","DOI":"10.1016\/j.rmed.2021.106712","article-title":"Utility of electrophysiologic testing for sudden death risk stratification in cardiac sarcoidosis patients with mildly impaired left ventricular function","volume":"191","author":"P Tandon","year":"2022","journal-title":"Respir Med"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1002\/ehf2.13614","article-title":"Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis","volume":"8","author":"Y Kobayahi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"2100449","DOI":"10.1183\/13993003.00449-2021","article-title":"Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies","volume":"59","author":"J Stievenart","year":"2021","journal-title":"Eur Resp J"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"e021183","DOI":"10.1161\/JAHA.121.021183","article-title":"Corticosteroid and immunosuppressant therapy for cardiac sarcoidosis: A systematic review","volume":"10(17)","author":"S Fazelpour","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"ref139","first-page":"1878","article-title":"Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review","volume":"76","author":"M G Triveri","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines fort he management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"21","author":"K Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jamacardio.2021.4738","article-title":"Outcomes associated with catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis","volume":"7","author":"K C Siontis","year":"2021","journal-title":"JAMA Cardiol"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"e0194496","DOI":"10.1371\/journal.pone.0194496","article-title":"Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator","volume":"13","author":"D Skowasch","year":"2018","journal-title":"PLoS One"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chest.2016.08.1457","article-title":"Cardiac sarcoidosis: the impact of age and implanted devices on survival","volume":"151","author":"Y Hou","year":"2017","journal-title":"Chest"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12350-017-1043-4","article-title":"A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology","volume":"25","author":"R HJA Slart","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2169\/internalmedicine.53.0794","article-title":"Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions","volume":"53","author":"S Nagai","year":"2014","journal-title":"Intern Med"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijcard.2016.10.101","article-title":"Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis","volume":"227","author":"S K Padala","year":"2017","journal-title":"Int J Cardiol"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.amjcard.2015.12.033","article-title":"Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis","volume":"117","author":"T Nagai","year":"2016","journal-title":"Am J Cardiol"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/heartjnl-2013-305187","article-title":"Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis","volume":"100","author":"T Ise","year":"2014","journal-title":"Heart"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Y Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chest.2016.08.1457","article-title":"Cardiac sarcoidosis: the impact of age and implanted devices on survival","volume":"151","author":"Y Zhou","year":"2017","journal-title":"Chest"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.amjcard.2015.06.021","article-title":"Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis","volume":"116","author":"R Kandolin","year":"2015","journal-title":"Am J Cardiol"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jcmg.2017.04.020","article-title":"Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis","volume":"11","author":"B W Sperry","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1253\/circj.CJ-14-1275","article-title":"Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis","volume":"79","author":"T Nagai","year":"2015","journal-title":"Circ J"},{"key":"ref154","first-page":"133","article-title":"Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block","volume":"20","author":"Y Kato","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"e003738","DOI":"10.1161\/CIRCIMAGING.115.003738","article-title":"Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance","volume":"9","author":"G Murtagh","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.acvd.2016.12.014","article-title":"Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors","volume":"110","author":"C Chapelon-Abric","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.md.0000145367.17934.75","article-title":"Cardiac sarcoidosis: a retrospective study of 41 cases","volume":"83","author":"C Chapelon-Abric","year":"2004","journal-title":"Medicine"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jcmg.2012.10.021","article-title":"CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis","volume":"6","author":"S Greulich","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/jce.12302","article-title":"Cardiac sarcoidosis: electrophysiological outcomes on long-term follow- up and the role of the implantable cardioverter-defibrillator","volume":"25","author":"A Mohsen","year":"2014","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12149-010-0376-8","article-title":"Myocardial washout of 99mTc-tetrofosmin and response to steroid therapy in patients with cardiac sarcoidosis","volume":"24","author":"H Kudoh","year":"2010","journal-title":"Ann Nucl Med"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study","volume":"131","author":"R Kandolin","year":"2015","journal-title":"Circulation"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1253\/circj.CJ-14-1217","article-title":"Association between basal thinning of interventricular septum and adverse long-term clinical outcomes in patients with cardiac sarcoidosis","volume":"79","author":"N Nagano","year":"2015","journal-title":"Circ J"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijcard.2014.07.042","article-title":"Reduction of myocardial inflammation with steroid is not necessarily associated with improvement in left ventricular function in patients with cardiac sarcoidosis: predictors of functional improvement","volume":"176","author":"Y Takaya","year":"2014","journal-title":"Int J Cardiol"},{"key":"ref164","first-page":"133","article-title":"Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block","volume":"20","author":"Y Kato","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref165","first-page":"16","article-title":"A case with cardiac sarcoidosis. Significance of the effect of steroids on the reversion of advanced atrioventricular block and myocardial scintigraphic abnormalities","volume":"5","author":"N Ujita","year":"1990","journal-title":"Heart Vessels Suppl"},{"key":"ref166","first-page":"210","article-title":"National survey on status of steroid therapy for cardiac sarcoidosis in Japan","volume":"22","author":"S Hiramitsu","year":"2005","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ehf2.12095","article-title":"Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction","volume":"3","author":"T Okabe","year":"2016","journal-title":"ESC Heart Fail"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijcard.2016.10.101","article-title":"Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis","volume":"227","author":"S K Padala","year":"2017","journal-title":"Int J Cardiol"},{"key":"ref169","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.14-0139","article-title":"Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation","volume":"146","author":"T Nagai","year":"2014","journal-title":"Chest"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"N A Khan","year":"2017","journal-title":"Respir Med"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"190146","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"F F Rahaghi","year":"2020","journal-title":"Eur Respir Rev"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ejhf.1319","article-title":"Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres","volume":"20","author":"L A Fussner","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chest.2016.08.1457","article-title":"Cardiac sarcoidosis: the impact of age and implanted devices on survival","volume":"151","author":"Y Zhou","year":"2017","journal-title":"Chest"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs","volume":"276","author":"T Ballul","year":"2019","journal-title":"Int J Cardiol"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2169\/internalmedicine.53.0794","article-title":"Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions","volume":"53","author":"S Nagai","year":"2014","journal-title":"Intern Med"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac sarcoidosis","volume":"124","author":"L J Harper","year":"2019","journal-title":"Am J Cardiol"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.semarthrit.2019.11.004","article-title":"TNF-alpha inhibition for the treatment of cardiac sarcoidosis","volume":"50","author":"M C Baker","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1513\/AnnalsATS.201902-119CME","article-title":"Update in cardiac sarcoidosis","volume":"16","author":"M L Ribeiro Neto","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.cjca.2013.02.004","article-title":"Corticosteroid therapy for cardiac sarcoidosis: a systematic review","volume":"29","author":"M M Sadek","year":"2013","journal-title":"Can J Cardiol"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Y Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chest.2016.08.1457","article-title":"Cardiac sarcoidosis: the impact of age and implanted devices on survival","volume":"151","author":"Y Zhou","year":"2017","journal-title":"Chest"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijcard.2016.10.101","article-title":"Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis","volume":"227","author":"S K Padala","year":"2017","journal-title":"Int J Cardiol"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"190145","DOI":"10.1183\/16000617.0145-2019","article-title":"Clinical phenotyping: role in treatment decisions in sarcoidosis","volume":"29","author":"R P Baughman","year":"2020","journal-title":"Eur Respir Rev"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1378\/chest.11-0263","article-title":"Management of cardiac sarcoidosis in the United States: a Delphi study","volume":"141","author":"N Y Hamzeh","year":"2012","journal-title":"Chest"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12350-017-1043-4","article-title":"A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology","volume":"25","author":"R HJA Slart","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1573403X15666190725121246","article-title":"Imaging in suspected cardiac sarcoidosis: a diagnostic challenge","volume":"16","author":"F J Ha","year":"2020","journal-title":"Curr Cardiol Rev"}],"container-title":["Pneumologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2259-1046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:51:32Z","timestamp":1730811092000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2259-1046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":185,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,2,28]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2259-1046","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0934-8387","1438-8790"],"issn-type":[{"value":"0934-8387","type":"print"},{"value":"1438-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}